627530-84-1 Usage
Uses
Used in Pharmaceutical Industry:
BMS 564929 is used as a therapeutic agent for the treatment of osteoporosis. It has the potential to increase bone density and strength, thereby reducing the risk of fractures and improving overall bone health.
Used in Sports and Fitness Industry:
BMS 564929 is used as a performance-enhancing substance by athletes and bodybuilders. Its anabolic effects can help improve muscle mass, strength, and endurance, making it a popular choice for those seeking to enhance their physical performance.
Used in Aging and Rehabilitation:
BMS 564929 is used as a supportive treatment for individuals experiencing muscle wasting and frailty due to aging or illness. Its anabolic effects can help improve muscle mass and function, leading to better overall health and quality of life.
Used in Research and Development:
BMS 564929 is used as a research tool to study the effects of androgen receptor modulation on various physiological processes. This can help scientists better understand the role of androgen receptors in health and disease, potentially leading to the development of new therapeutic agents and treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 627530-84-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,7,5,3 and 0 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 627530-84:
(8*6)+(7*2)+(6*7)+(5*5)+(4*3)+(3*0)+(2*8)+(1*4)=161
161 % 10 = 1
So 627530-84-1 is a valid CAS Registry Number.
627530-84-1Relevant academic research and scientific papers
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators
Hamann, Lawrence G.,Manfredi, Mark C.,Sun, Chongqing,Krystek Jr., Stanley R.,Huang, Yanting,Bi, Yingzhi,Augeri, David J.,Wang, Tammy,Zou, Yan,Betebenner, David. A.,Fura, Aberra,Seethala, Ramakrishna,Golla, Rajasree,Kuhns, Joyce E.,Lupisella, John A.,Darienzo, Celia J.,Custer, Laura L.,Price, Jennifer L.,Johnson, James M.,Biller, Scott A.,Zahler, Robert,Ostrowski, Jacek
, p. 1860 - 1864 (2008/02/04)
Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.
